IDEXX Laboratories - IDXX Stock Forecast, Price & News

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on IDXX. Bank of America lowered shares of IDEXX Laboratories from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $550.00 to $470.00 in a research report on Thursday, May 5th. Atlantic Securities dropped their price target on IDEXX Laboratories from $500.00 to $490.00 and set an "overweight" rating for the company in a research report on Wednesday, August 3rd. Morgan Stanley reduced their price objective on IDEXX Laboratories from $603.00 to $573.00 and set an "overweight" rating on the stock in a research report on Thursday, August 4th. Barclays dropped their target price on IDEXX Laboratories from $700.00 to $582.00 and set an "overweight" rating for the company in a report on Friday, August 5th. Finally, StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Monday, July 25th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of "Moderate Buy" and an average target price of $519.38.

IDEXX Laboratories Trading Down 0.9 %

NASDAQ:IDXX opened at $396.68 on Friday. The company has a debt-to-equity ratio of 1.68, a current ratio of 0.89 and a quick ratio of 0.61. The stock has a market capitalization of $33.02 billion, a P/E ratio of 51.18, a PEG ratio of 5.33 and a beta of 1.14. The firm's 50-day moving average is $369.63 and its two-hundred day moving average is $441.22. IDEXX Laboratories has a 12 month low of $318.50 and a 12 month high of $695.18.